Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

Vaccines are one of the most important medical inventions of modern times that have saved and enhanced innumerable lives around the world. Despite the technological advances in vaccine design and ...

Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG ("Aicuris") today announced that the company will be presenting the results of pritelivir from their pivotal Phase 3 trial (PRIOH ...

Herpes simplex virus (HSV) types 1 and 2 are globally prevalent viruses that establish chronic infections and cause painful ulcers during reactivation periods. Although HSV-1 primarily causes ...

CAMBRIDGE, Mass., March 18, 2013 /PRNewswire/ -- Genocea Biosciences Inc., a clinical-stage company pioneering novel T cell vaccines, announced today the publication of new data to support GEN-003, ...

HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...

Dear Dr. Roach: I am a healthy man in my late 40s. I was married for 18 years to my first sexual partner. Since my divorce three years ago, I have had two additional partners. These were casual flings ...